Shandong Keyuan Pharmaceutical Co., Ltd. (SHE:301281)

China · Delayed Price · Currency is CNY

50.07

-0.11 (-0.22%)

At close: Jun 18, 2026

48.93% (1Y)

Market Cap	5.43B +49.4%
Revenue (ttm)	448.33M +4.6%
Net Income	23.54M -62.0%
EPS	0.21 -62.9%
Shares Out	108.29M
PE Ratio	235.23
Forward PE	n/a
Dividend	0.05 (0.10%)
Ex-Dividend Date	Jun 16, 2026

Volume	3,195,435
Open	49.98
Previous Close	50.18
Day's Range	49.30 - 50.97
52-Week Range	25.87 - 53.99
Beta	0.00
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About SHE:301281

Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of chemical raw materials and their preparations. It offers gliclazide; metformin hydrochloride; isosorbide mononitrate; isosorbide dinitrate; lansoprazole; mecobalamin; ropivacaine hydrochloride; isoflurane; fluoxetine hydrochloride; clemastine fumarate; chlorpheniramine maleate; esmolol hydrochloride; nicotinamide-tinidazole; amlexanox; nisoldipine; qupibutu; clarithromycin lactobionate; propafenone hydrochloride; potassium diclofe... [Read more]

Industry Drug Manufacturers - General

Sector Healthcare

Founded 2004

Employees 650

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301281

Full Company Profile

Financial Performance

In 2025, SHE:301281's revenue was 398.23 million, a decrease of -14.12% compared to the previous year's 463.72 million. Earnings were 16.55 million, a decrease of -72.62%.

Financial Statements